CRIS Current Research Information System

IACOBUCCI, ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.956
AS - Asia 15.003
EU - Europa 12.030
AF - Africa 919
SA - Sud America 829
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 13
Totale 44.770
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.733
SG - Singapore 3.987
CN - Cina 3.944
VN - Vietnam 3.867
GB - Regno Unito 3.466
SE - Svezia 1.989
DE - Germania 1.457
IT - Italia 1.395
HK - Hong Kong 854
IN - India 807
FR - Francia 756
RU - Federazione Russa 627
BR - Brasile 591
IE - Irlanda 404
NL - Olanda 403
UA - Ucraina 360
ZA - Sudafrica 310
JP - Giappone 300
KR - Corea 244
EE - Estonia 235
CH - Svizzera 190
FI - Finlandia 185
BD - Bangladesh 183
TG - Togo 183
GR - Grecia 164
CA - Canada 149
CI - Costa d'Avorio 149
NG - Nigeria 115
PH - Filippine 113
AR - Argentina 109
BG - Bulgaria 107
JO - Giordania 102
IR - Iran 96
SC - Seychelles 70
TR - Turchia 68
ID - Indonesia 64
BE - Belgio 60
IQ - Iraq 59
TH - Thailandia 58
PL - Polonia 56
AT - Austria 47
ES - Italia 42
TW - Taiwan 41
MX - Messico 36
EC - Ecuador 32
PK - Pakistan 30
SA - Arabia Saudita 30
UZ - Uzbekistan 30
MY - Malesia 27
LB - Libano 21
CZ - Repubblica Ceca 18
AU - Australia 17
CL - Cile 17
CO - Colombia 17
EG - Egitto 17
PY - Paraguay 17
PE - Perù 16
VE - Venezuela 16
KE - Kenya 14
TN - Tunisia 13
MA - Marocco 12
AE - Emirati Arabi Uniti 11
HR - Croazia 11
EU - Europa 10
RO - Romania 10
ET - Etiopia 9
LT - Lituania 9
TM - Turkmenistan 9
DZ - Algeria 8
KZ - Kazakistan 8
IL - Israele 7
RS - Serbia 7
MU - Mauritius 6
OM - Oman 6
GY - Guiana 5
HN - Honduras 5
MD - Moldavia 5
SK - Slovacchia (Repubblica Slovacca) 5
AL - Albania 4
AZ - Azerbaigian 4
BB - Barbados 4
BO - Bolivia 4
JM - Giamaica 4
KG - Kirghizistan 4
NI - Nicaragua 4
NP - Nepal 4
PA - Panama 4
PS - Palestinian Territory 4
PT - Portogallo 4
QA - Qatar 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AO - Angola 3
NZ - Nuova Zelanda 3
SI - Slovenia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
Totale 44.727
Salva come PNG Salva come JPEG
Città #
Southend 3.194
Singapore 2.750
Ashburn 1.509
Fairfield 1.499
Chandler 1.311
Dong Ket 981
San Jose 918
Houston 828
Hong Kong 812
Wilmington 756
Woodbridge 720
Seattle 649
Beijing 600
Princeton 599
Ho Chi Minh City 596
Ann Arbor 564
Hanoi 540
Hefei 531
Cambridge 506
Santa Clara 498
Dublin 403
Boardman 384
Westminster 295
Lauterbourg 291
Nanjing 290
Padova 263
Tokyo 244
Bologna 243
Los Angeles 223
New York 204
Lomé 183
Seoul 179
Medford 169
Bern 158
Helsinki 157
Jacksonville 156
Jinan 154
Abidjan 149
Shenyang 144
Dallas 142
Saint Petersburg 134
Berlin 130
Buffalo 113
Hebei 105
Nanchang 105
Changsha 104
Milan 104
Sofia 104
Amman 101
Redondo Beach 96
Frankfurt am Main 95
San Diego 95
São Paulo 91
Munich 90
Redmond 86
Da Nang 81
Haiphong 80
Turin 80
Falls Church 77
Tianjin 77
Bremen 75
Abeokuta 70
Shanghai 70
Guangzhou 68
Zhengzhou 65
Florence 61
Jiaxing 60
Hangzhou 59
Brussels 58
Council Bluffs 55
Bengaluru 51
Mülheim 51
Norwalk 50
Orem 50
Haikou 49
Redwood City 48
Toronto 48
Phoenix 42
Ningbo 41
Warsaw 36
Athens 35
Istanbul 35
Mountain View 35
Baghdad 34
Hải Dương 34
Kunming 34
London 34
Rome 34
Taiyuan 34
Taizhou 34
Amsterdam 32
Chicago 31
Bangkok 30
Jakarta 30
Johannesburg 30
Mahé 30
Vienna 30
Dearborn 29
Hyderabad 29
Xi'an 29
Totale 28.490
Salva come PNG Salva come JPEG
Nome #
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 390
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 355
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 349
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 343
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 337
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 315
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 315
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 305
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 305
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 304
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 297
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 295
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 285
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy 276
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 275
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 267
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 266
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 256
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 253
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 244
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 241
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 239
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 237
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 234
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 228
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 227
WHOLE TRANSCRIPTOME DEEP-SEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 226
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 223
A case report of acute myeloid leukemia and neurofibromatosis 1 223
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 223
Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial 222
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 222
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 219
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 219
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 217
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 215
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 214
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 213
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 213
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 212
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 211
A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia 211
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 210
RALE051: a novel established cell line of sporadic Burkitt lymphoma 209
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 208
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 206
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 203
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 203
c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration 202
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 201
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 200
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 200
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 200
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 199
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. 196
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 196
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. 194
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 194
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 192
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 191
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 190
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 190
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis 189
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 189
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 189
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 189
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 187
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 186
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 186
The cell cycle checkpoint inhibitors in the treatment of leukemias 185
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 185
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 185
Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model 183
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 181
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 181
Association between transporters genotype and response to the treatment in a subset of previously untreated chronic myeloid leukemia patients enrolled into the tops trial. 179
AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile. 179
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 178
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 177
Clec12a: A new AML stem cell-associated antigen 177
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 177
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 176
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 175
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 175
A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 175
EFFICACY AND FEASIBILITY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): A SINGLE-CENTER EXPERIENCE 175
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 174
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. 173
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 172
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 170
Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients 169
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 169
Override the doxorubicin-induced G2/M checkpoint using cell-cycle checkpoint inhibitors on acute lymphoblastic leukemia 169
SNP array reveals a new deletion of JAK2 in AML patients 169
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 167
Identification of Rab5 as a Gene Involved in Chronic Myeloid Leukemia (CML) Progression 166
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 165
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 164
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia 164
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 163
Totale 21.617
Salva come PNG Salva come JPEG
Categoria #
all - tutte 117.628
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 117.628
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.642 0 0 0 0 0 0 0 0 0 0 0 1.642
2021/20225.675 686 129 403 489 576 397 104 364 273 397 917 940
2022/20235.645 685 919 291 734 391 440 184 329 870 126 400 276
2023/20241.460 63 241 62 123 105 355 110 81 61 63 87 109
2024/20255.384 230 879 459 356 815 281 392 144 43 494 198 1.093
2025/202612.894 927 1.116 1.196 818 1.436 775 1.258 669 2.823 1.158 507 211
Totale 45.565